Accuray Incorporated (ARAY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed results: strong service revenue growth and improved gross margins are positives, but declining product revenue and geopolitical tensions are concerning. Tariff impacts and economic slowdowns add uncertainty. The Q&A highlights optimism for the U.S. market and emerging markets, yet cautiousness remains. Overall, the sentiment is balanced with no clear catalyst for significant short-term stock movement.
Key Financial Performance
Total Revenue (Q4) $128 million, down 5% year-over-year. Decline driven by lower product revenue in China and EIMEA due to geopolitical tensions and tariffs.
Service Revenue (Q4) $56.9 million, up 4% year-over-year. Growth attributed to an expanding installed base and strategic pricing initiatives.
Product Revenue (Q4) $71 million, down 11% year-over-year. Decline due to regional dynamics, including tariff impacts in China and unrest in the Middle East.
Gross Margin (Q4) 30.6%, up 200 basis points year-over-year. Improvement driven by service margin growth, though product margins were impacted by deferred margins in China.
Adjusted EBITDA (Q4) $9.4 million. Impacted by $1.7 million higher margin deferral into future quarters due to regional revenue shifts.
Total Revenue (Full Year) $459 million, up 3% year-over-year. Growth driven by strong international performance, particularly in APAC and China.
Service Revenue (Full Year) $221 million, up 4% year-over-year. Growth driven by increased service contract capture rates and value-added offerings.
Product Revenue (Full Year) $238 million, up 1.5% year-over-year. Growth in APAC and China offset by declines in developed markets like EIMEA and Japan.
Gross Margin (Full Year) 32.1%, up 10 basis points year-over-year. Improvement driven by service margin growth and operational efficiencies.
Adjusted EBITDA (Full Year) $28.3 million, up 44% year-over-year. Growth driven by cost control and operational improvements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Tomo C and Helix: New product innovations like Tomo C for China and Helix in international markets have been central to growth strategy. These products are seeing strong demand in emerging markets.
CyberKnife S7: Expected to gain traction as the only robotic dedicated SRS, SBRT system.
Emerging Markets: Majority of revenue now comes from emerging markets, with a CAGR of approximately 9% over the last 3 years. Strong growth in APAC (22% in Q4) and China (20% YoY).
Developed Markets: U.S. market shows signs of recovery with 24% revenue growth in Q4, though replacement market remains slow.
Service Revenue: Service revenue grew 4% YoY in Q4 and for the full year, driven by an expanded installed base and strategic pricing. Service margins improved due to reduced parts consumption and pricing initiatives.
Tariff Mitigation: Implemented duty drawback programs, foreign trade zone establishment, and dual sourcing to mitigate tariff impacts.
Debt Refinancing: Completed refinancing with TCW, securing $190 million in new financing, extending debt maturity by 5 years, and improving financial flexibility.
Focus on Emerging Markets: Targeting high-growth markets like China and APAC with products like Tomo C and Helix.
Operational Efficiency: Launched initiatives to simplify processes, use generative AI tools, and optimize pricing to accelerate margin expansion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical Environment: Turbulent geopolitical environment impacted key regions, including trade negotiations between the U.S. and China and unrest in the Middle East, causing disruptions in shipments and supply chain challenges.
Tariff Volatility: The U.S. and China imposed high tariffs on goods, which were later reduced but caused significant disruptions in revenue and supply chain operations, particularly in China and EIMEA regions.
Regional Revenue Declines: Revenue declined in key regions such as China (14%), EIMEA (34%), and Japan (11%) due to geopolitical tensions, tariffs, and economic slowdowns.
Supply Chain Challenges: Significant challenges in pivoting supply chain operations to deliver products to different regions due to geopolitical and economic disruptions.
Service Business Growth Limitations: While service revenue grew, the U.S. market remained flat, and the Americas saw a 7% decline in service revenue, limiting overall growth potential.
Economic Slowdowns: Economic slowdowns in developed markets like Japan and the U.S. impacted product revenue and order demand.
Capital Equipment Budget Cycles: Near-term challenges in capital equipment budget cycles in developed markets like the U.S. affected revenue growth.
Tariff Costs: The company incurred approximately $4 million in cash tariffs in Q4, with ongoing efforts to mitigate these costs through duty drawback programs and foreign trade zone establishment.
Operational Costs: Increased operating expenses in Q4 due to R&D and marketing investments, impacting short-term profitability.
Market Uncertainties: Continued market uncertainties and macroeconomic dynamics pose risks to revenue and operational performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for FY 2026: The company is guiding to a revenue range of $471 million to $485 million for fiscal year 2026.
Adjusted EBITDA Guidance for FY 2026: The company is guiding to an adjusted EBITDA range of $31 million to $35 million for fiscal year 2026.
Growth in Installed Base: The company expects its installed base to grow substantially in FY 2026, driven by a strong backlog of installations from fiscal year 2025. This growth will contribute to revenue and margin expansion in the long term.
Emerging Markets Strategy: The company plans to continue its focus on emerging markets, with a full year of Tomo C products in China and plans to enter other high-growth emerging markets with Helix.
New Product Launches: The company will showcase new solutions around adaptive radiotherapy at ASTRO in October, targeting the U.S. and developed markets. These solutions aim to provide advanced radiotherapy capabilities for the aged installed base.
CyberKnife S7 Momentum: The company expects continued traction for the CyberKnife S7 system, emphasizing its unique capabilities as the only robotic dedicated SRS, SBRT system.
Operational Efficiency Initiatives: The company has launched an internal initiative to accelerate margin expansion by simplifying processes, leveraging generative AI tools, reducing indirect costs, and optimizing pricing tied to customer value.
Cautious Outlook on Market Uncertainties: The company remains cautious about continued market uncertainties and macro and geopolitical dynamics, which have historically been a headwind to performance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the current situation in China regarding customer demand and tariffs?
A:Suzanne Winter stated that the situation in China has improved compared to the end of Q3, but it has not completely returned to normal. Customer demand for products remains strong, and the Type B strategy is working well. However, funding for Type A market licenses is slower from the government. Ali Pervaiz added that tariffs have been extended for another 90 days, and the situation remains uncertain.
Q:Is the foreign trade exemption zone assumed in the guidance for fiscal '26?
A:Suzanne Winter confirmed that the foreign trade exemption zone is assumed in the guidance.
Q:What is driving optimism about the U.S. market improving throughout the fiscal year?
A:Suzanne Winter mentioned strong Q4 performance in the Americas, efforts to convert backlog and accelerate installations, and upcoming new solutions targeted for premium developed markets as reasons for optimism. However, there is still cautiousness in the U.S. market regarding orders.
Q:What is the outlook for Helix in India and other emerging markets?
A:Suzanne Winter stated that Helix had a solid first year, with regulatory approval in India now in place. Growth is expected in FY '26 in India, Bangladesh, Morocco, and Latin America. The comprehensive portfolio allows addressing diverse customer needs.
Q:What is the expected impact of tariffs on the fiscal year '26 financials?
A:Ali Pervaiz explained that there was a $4 million cash impact from tariffs this quarter, half of which was mitigated. The other half is capitalized into inventory and will impact the P&L over the next few quarters. This run rate is assumed in the fiscal '26 guidance.
Q:How is the revenue and EBITDA profile expected to trend in fiscal year '26?
A:Ali Pervaiz stated that 45% of revenue is expected in the first half and 55% in the second half of fiscal '26. EBITDA contribution is expected to be 30% in the first half and 70% in the second half, aligning with volume trends.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear answer regarding the long-term outlook for tariffs in China, as they stated the situation remains uncertain and could change at any point.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounts
China EIMEA
EIMEA decline
EIMEA region
Japan China
LLC Research
Middle East
RD investment
Research Division
Service highlight
States cash
TCW
Tomo China
United States
ability tariff
adjustment
base service
basis point
custom
debt
duty
factor
margin deferral
plan
refinancing
service contract
service margin
service part
tariff good
timing
trade zone
transaction
ARAY Transcript
Accuray Incorporated (ARAY) Q3 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary shows strong financial performance with increased revenue, gross margin, and net income, which is positive. However, the lack of strategic updates and reduced guidance for revenue and EBITDA suggest caution. The Q&A section did not provide additional insights, and potential regulatory challenges add uncertainty. This mixed information leads to a neutral sentiment, as positive financials are offset by concerns about future guidance and risks.
Accuray Incorporated (ARAY) Q2 2026 Earnings Call Transcript
Unknown2-4
The earnings call reveals several negative factors: a decline in net revenue and gross margins, geopolitical tensions affecting product revenue, and reduced revenue guidance. Additionally, workforce reductions and restructuring charges highlight financial strain, while cash flow concerns further dampen sentiment. Although there are some positive aspects, such as service revenue growth and potential new initiatives, the overall picture is negative due to financial challenges and uncertainties.
Accuray Incorporated (ARAY) Q1 2026 Earnings Call Transcript
Unknown11-5
The earnings call summary reveals a decline in net and product revenues, a significant drop in gross margins, and an increased operating loss. Despite a strong order backlog and stable cash position, geopolitical issues in key markets and unclear management responses in the Q&A section contribute to negative sentiment. The guidance suggests a back-loaded fiscal year, but current challenges overshadow potential future improvements. The lack of clarity in management's answers, particularly regarding tariffs and order cancellations, further exacerbates concerns, leading to an overall negative outlook for stock price movement.
Accuray Incorporated (ARAY) Q4 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals mixed results: strong service revenue growth and improved gross margins are positives, but declining product revenue and geopolitical tensions are concerning. Tariff impacts and economic slowdowns add uncertainty. The Q&A highlights optimism for the U.S. market and emerging markets, yet cautiousness remains. Overall, the sentiment is balanced with no clear catalyst for significant short-term stock movement.
ARAY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
